Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-28T20:02:51.528Z Has data issue: false hasContentIssue false

Authors' reply

Published online by Cambridge University Press:  02 January 2018

Mathew Hoskins
Affiliation:
Cardiff University, Cardiff, UK
Jennifer Pearce
Affiliation:
Cardiff University, Cardiff, UK
Andrew Bethell
Affiliation:
Cardiff University, Cardiff, UK
Corrado Barbui
Affiliation:
University of Verona, Verona, Italy
Wietse A. Tol
Affiliation:
Johns Hopkins Bloomberg School of Public Health, Baltimore, USA
Soraya Seedat
Affiliation:
Stellenbosch University, Stellenbosch, South Africa
Hanhui Chen
Affiliation:
Shanghai Jiaotong University, Shanghai, China
Jonathan I. Bisson
Affiliation:
Institute of Psychological Medicine and Clinical Neurosciences, Cardiff University School of Medicine, Cardiff, UK. Email: [email protected]
Rights & Permissions [Opens in a new window]

Abstract

Type
Columns
Copyright
Copyright © Royal College of Psychiatrists, 2015 

I read with interest the systematic review of pharmacotherapy for post-traumatic stress disorder (PTSD) by Mathew Hoskins and colleagues. Looking at Fig. 2 of the paper and at the online-only supplemental file, however, it seems to me that two unpublished studies have been counted twice in the meta-analysis. As far as I can see from the information reported in the review, the study ‘Eli Lilly’ is the same as ‘Martenyi 2007’ and ‘Pfizer 589’ is the same as ‘Friedman 2007’ (same drugs, same comparisons, same sample size). I would be grateful if the authors could clarify the matter.

References

1 Hoskins, M Pearce, J Bethell, A Dankova, L Barbui, C Tol, QA. Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis. Br J Psychiatry 2015; 206: 93100.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.